Industry Focus

Hit or miss data, delays, and contentious debate preceded the FDA's green-lighting of the first drug to target the cause of Duchenne muscular dystrophy.

Direct download: 20160921_IF_Healthcare.mp3
Category:Podcast -- posted at: 3:30pm EST